Huntington’s Disease News and Research

RSS

New laboratory model for Huntington's disease

Cedars-Sinai scientists have joined with expert colleagues around the globe in using stem cells to develop a laboratory model for Huntington's disease, allowing researchers for the first time to test directly on human cells potential treatments for this fatal, inherited disorder.

29 Jun 2012

Researchers create 'Huntington's disease in a dish' to enable search for treatment

Johns Hopkins researchers, working with an international consortium, say they have generated stem cells from skin cells from a person with a severe, early-onset form of Huntington's disease (HD), and turned them into neurons that degenerate just like those affected by the fatal inherited disorder.

29 Jun 2012

GMCSF linked with rapid cognitive recovery in patients with cancer

Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.

23 Jun 2012

North Shore-LIJ Health System acquires 15 GE low-dose CT scanners

In the interest of advancing patient safety and improving care, the North Shore-LIJ Health System today announced with GE Healthcare the $12 million purchase of 15 GE Low-Dose CT Scanners that will be installed at 10 locations throughout the New York area over the next year.

22 Jun 2012

States wonder: What happens to us after health law ruling?

States are anxiously considering the effect of the pending court decision. In Florida, Gov. Rick Scott says his state will comply with the health law if it is upheld. And in California, officials and lawmakers worry over what a ruling could mean for plans to institute consumer protections.

22 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.

21 Jun 2012

Implanted device delivers genetically engineered neurotrophic factor directly to the brain

Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.

19 Jun 2012

New U-M hESC lines now available for federally-funded research

Six new human embryonic stem cell lines derived at the University of Michigan have just been placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research.

15 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

14 Jun 2012

dSarm/Sarm1 gene promotes axon destruction after injury

Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy.

8 Jun 2012

MGH, HSG to conduct PBT2 clinical trial in Huntington's disease

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.

8 Jun 2012

New research into cell-damaging effects of Huntington's disease

New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.

7 Jun 2012

Use of transplanted induced pluripotent stem cells could lead to new treatments for HD

Researchers from South Korea, Sweden, and the United States have collaborated on a project to restore neuron function to parts of the brain damaged by Huntington's disease (HD) by successfully transplanting HD-induced pluripotent stem cells into animal models.

30 May 2012

Brain cells prune circuits in the brain by eating away excess synapses

We’re born with our brains prewired, but as information comes in from our environment, this circuitry is updated. A study from Boston Children’s Hospital provides a new glimpse of how this happens: Brain cells known as microglia, tuned into the crosstalk between neurons, literally engulf unnecessary connections, known as synapses, and prune them away.

24 May 2012

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington's disease (HD). Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.

21 May 2012

Regenerative medicine researchers explore innovative ways to treat childhood conditions

About 3 percent of the babies born in the United States have a birth defect. Children without a birth defect are also susceptible to injury or disease. At The University of Texas Health Science Center at Houston (UTHealth), regenerative medicine researchers are exploring innovative ways to treat these conditions.

21 May 2012

CHDI, KineMed partner to investigate turnover rates of huntingtin protein

KineMed, Inc. and CHDI Foundation, Inc. announced today a collaboration to use KineMed's isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pathogenesis of Huntington's disease (HD).

15 May 2012

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

In a study, published in Nature, researchers prevented brain cells dying in mice with prion disease. It is hoped the same method for preventing brain cell death could apply in other diseases. The findings are at an early stage, but have been heralded as “fascinating”.

8 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Huntington’s Disease News and Research

New laboratory model for Huntington's disease

Researchers create 'Huntington's disease in a dish' to enable search for treatment

GMCSF linked with rapid cognitive recovery in patients with cancer

North Shore-LIJ Health System acquires 15 GE low-dose CT scanners

States wonder: What happens to us after health law ruling?

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

Implanted device delivers genetically engineered neurotrophic factor directly to the brain

New U-M hESC lines now available for federally-funded research

New analogues effective in inhibiting NOS activity in Parkinson models

dSarm/Sarm1 gene promotes axon destruction after injury

MGH, HSG to conduct PBT2 clinical trial in Huntington's disease

New research into cell-damaging effects of Huntington's disease

Use of transplanted induced pluripotent stem cells could lead to new treatments for HD

Brain cells prune circuits in the brain by eating away excess synapses

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

Regenerative medicine researchers explore innovative ways to treat childhood conditions

CHDI, KineMed partner to investigate turnover rates of huntingtin protein

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

Alnylam first quarter revenues decrease to $20.6 million

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News